Company:  VERONA PHARMA PLC (VRNA)
Form Type:  S-3ASR
Filing Date:  3/7/2023 
CIK:  0001657312 
Address:  3 MORE LONDON RIVERSIDE 
City, State, Zip:  LONDON,  SE1 2RE 
Telephone:  011-44-0-2032834200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$21.70  
Change: 
0.24 (1.12%)  
Trade Time: 
09:38 AM EST  
Market Cap: 
$13.79B
Trade VRNA now with 

© 2023  
Description of Business
We were incorporated in February 2005 under the laws of England and Wales with the Registrar of Companies of England and Wales under the name Isis Resources plc. In September 2006, we acquired Rhinopharma Limited, a private company incorporated in Canada, and changed our name to Verona Pharma plc. Our principal office is located at 3 More London Riverside, London SE1 2RE, United Kingdom, and our telephone number is +(44) 203 283 4200. The principal legislation under which we operate is the Companies Act 2006. Our agent for service of process in the United States is Cogency Global Inc., whose address is 10 E. 40th Street, 10th floor, New York, New York 10016. Our principal capital expenditures for the year ended December 31, 2019 were £0.3 million (2018: £0.3 million, 2017: £0.2 million). These capital expenditures primarily consisted of patent costs.
Register and access this filing in:     
  FORM S-3ASR
    EXPLANATORY NOTE
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
    RISK FACTORS
    USE OF PROCEEDS
    DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION
      NAME AND TITLE
    DESCRIPTION OF AMERICAN DEPOSITARY SHARES
    DESCRIPTION OF DEBT SECURITIES
    No Personal Liability of Directors, Officers, Employees or ...
    DESCRIPTION OF OTHER SECURITIES
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    EXPERTS
    THE OFFERING
    Use of Proceeds
    Risk Factors
    RISK FACTORS
    USE OF PROCEEDS
    DIVIDEND POLICY
    DILUTION
    PART II
      Item 14. Other Expenses of Issuance and Distribution
      Item 15. Indemnification of Directors and Officers
      Item 16. Exhibits
      BENEFICIAL OWNERS
      Item 17. Undertakings
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT 1.2
  EXHIBIT 4.4
  EXHIBIT 5.1
  EXHIBIT 5.2
  EXHIBIT 23.3
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT FILING FEES

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.